Advanced modalities in Trial Watch Edition 14 are defined by a shift from therapy development to therapy infrastructure.
CSL Behring is testing IgPro20 in secondary immune deficiency after CAR T and T cell redirecting therapy. This is the first Phase 3 focused on hypogammaglobulinemia as a distinct post CAR T and BiTE supportive care category.
Janssen is also testing ramantamig with prophylactic tocilizumab to reduce cytokine release syndrome risk in relapsed or refractory multiple myeloma.
The message is important. Cell therapy and bispecific volume is now large enough that supportive care itself is becoming a clinical development category.